

NEWS RELEASE

Solasia

Notice of Review Progress of Sancuso® in China

Tokyo, Japan, June 27th, 2018 - Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter "Solasia") announced today that the review for the New Drug Approval of Sancuso® (SP-01) at the Center for Drug Evaluation (CDE) has been completed and presented to the China National Drug Administration (CNDA).

About Solasia:

Solasia is a specialty pharmaceutical company based in Asia, with a mission of "Better Medicine for a Brighter Tomorrow". In order to address the unmet medical needs within the oncology area, we develop innovative medicines to contribute to the patient's healthy living and to provide treatment options for the healthcare providers.

Additional information is available at <http://www.solasia.co.jp/en/>

(Contacts)

Solasia Pharma K.K.

Rie Toyoda
Investor Relations
+81-3-5843-8049
info@solasia.co.jp